AdelCherguiDO

PubMed

• 2 citations
  Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress.
  Adel Chergui, John L Reagan> ;Cancers. 2023 Aug 17
• Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
  Matthew J Hadfield, Hetal Mistry, Ari Pelcovits, Rani Bansal, Sarah Andrea, Adel Chergui, Kristy Ramphal, Matthew Austin, Humera Khurshid> ;American Journal of Clinical Oncology. 2023 Apr 1
• Splenic Laceration: A Rare Complication of Abdominal Paracentesis.
  Ari B. Friedman, Adel Chergui, Ephraim Leiderman> ;Cureus. 2020 Oct 1
• Differential Efficacy of Anti-VEGF Antibodies Based on Sex and Race in a Diverse Cohort of Advanced Nonsquamous Non-Small Cell Lung Cancer.
  Vineeth Sukrithan, Alexander Barbaro, Adel Chergui, Brian Ko, Juan Lin, Haiying Cheng, Sanjay Goel> ;American Journal of Clinical Oncology. 2020 Jan 1
• 7 citations
  Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1).
  Alun Bermingham, Edmund Price, Christophe Marchand, Adel Chergui, Alena Naumova, Emily L. Whitson, Lauren R.H. Krumpe, Ekaterina I. Goncharova, Jason R. Evans, Tawnya ...> ;SLAS Discovery. 2017 Jul 11
• 19 citations
  Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform
  Junko Murai, Christophe Marchand, Sampada A. Shahane, Hongmao Sun, Ruili Huang, Yiping Zhang, Adel Chergui, Jiuping Ji, James H. Doroshow, Ajit Jadhav, Shunichi Takeda...> ;DNA Repair. 2014 Sep 1
• 16 citations
  Biochemical Assays for the Discovery of TDP1 Inhibitors
  Christophe Marchand, Shar-yin N. Huang, Thomas S. Dexheimer, Wendy A. Lea, Bryan T. Mott, Adel Chergui, Alena Naumova, Andrew G. Stephen, Andrew S. Rosenthal, Ganesha ...> ;Molecular Cancer Therapeutics. 2014 Aug 1
• 33 citations
  Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ri...
  Maulik R. Patel, Aaditya Bhatt, Jamin D. Steffen, Adel Chergui, Junko Murai, Yves Pommier, John M. Pascal, Louis D. Trombetta, Frank R. Fronczek, Tanaji T. Talele> ;Journal of Medicinal Chemistry. 2014 Jun 25
• 48 citations
  Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer...
  Daniel E. Beck, Keli Agama, Christophe Marchand, Adel Chergui, Yves Pommier, Mark Cushman> ;Journal of Medicinal Chemistry. 2014 Feb 27
• 53 citations
  Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1)
  Martin Conda-Sheridan, P. V. Narasimha Reddy, Andrew Morrell, Brooklyn T. Cobb, Christophe Marchand, Keli Agama, Adel Chergui, Amelie Renaud, Andrew G. Stephen, Lakshm...> ;Journal of Medicinal Chemistry. 2013 Jan 10
• 40 citations
  5-Arylidenethioxothiazolidinones as Inhibitors of Tyrosyl-DNA Phosphodiesterase i
  Venkata Ramana Sirivolu, Sanjeev Kumar V. Vernekar, Christophe Marchand, Alena Naumova, Adel Chergui, Amelie Renaud, Andrew G. Stephen, Feng Chen, Yuk Y. Sham, Yves Po...> ;Journal of Medicinal Chemistry. 2012 Oct 8
• 1 citations
  Correction to Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)-Topoisomerase I (Top1) Inhibitors.
  Trung Xuan Nguyen, Andrew Morrell, Martin Conda-Sheridan, Christophe Marchand, Keli Agama, Alun Bermingham, Andrew G. Stephen, Adel Chergui, Alena Naumova, Robert P. F...> ;Journal of Medicinal Chemistry. 2012 Aug 23
• 59 citations
  Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)–Topoisomerase I (Top1) Inhibitors
  Trung Xuan Nguyen, Andrew Morrell, Martin Conda-Sheridan, Christophe Marchand, Keli Agama, Alun Bermingam, Andrew G. Stephen, Adel Chergui, Alena Naumova, Robert J. Fi...> ;Journal of Medicinal Chemistry. 2012 May 10
• Join now to see all

Lectures

• Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with immunotherapy: A real-world retrospective study. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020